TRIPS Waiver

Op-ed: David Kappos and Andrei Iancu, “The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments,” STAT, 1/31/2024

January 31, 2024 No Comments

Op-ed: Judge Paul Michel, “Waiving COVID-19 IP Protections Would Harm US Industry,” Law360, 1/4/2024

January 4, 2024 No Comments

Press Release: Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver, 12/5/2023

December 5, 2023 No Comments

C4IP Letter to President Biden on Covid-19 IP Waiver Proposal, 12/4/2023

December 4, 2023 No Comments

Press Release: Council for Innovation Promotion Statement on ITC TRIPS Waiver Report, 10/18/2023

October 18, 2023 No Comments

Op-ed: Frank Cullen, “The Biden administration is endangering intellectual property rights,” The Dallas Morning News, 6/20/2023

June 20, 2023 No Comments

Blog: Fact Check: An Expanded TRIPS Waiver is Unnecessary, 5/3/2023

May 3, 2023 No Comments

C4IP Written Submission for Inv. No. 332-596, 4/26/2023

April 26, 2023 No Comments

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

March 29, 2023 No Comments

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

March 29, 2023 No Comments

Blog: USTR: Don’t let opposition to TRIPS waiver expansion stop here, 12/6/2022

December 6, 2022 No Comments

Webinar: Unpacking the Proposed TRIPS Waiver Expansion: A Conversation with Gary Locke, 12/1/2022

December 1, 2022 No Comments

Op-ed: David Kappos and Andrei Iancu, “The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments,” STAT, 1/31/2024

January 31, 2024

Op-ed: Judge Paul Michel, “Waiving COVID-19 IP Protections Would Harm US Industry,” Law360, 1/4/2024

January 4, 2024

Press Release: Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver, 12/5/2023

December 5, 2023

C4IP Letter to President Biden on Covid-19 IP Waiver Proposal, 12/4/2023

December 4, 2023

Press Release: Council for Innovation Promotion Statement on ITC TRIPS Waiver Report, 10/18/2023

October 18, 2023

Op-ed: Frank Cullen, “The Biden administration is endangering intellectual property rights,” The Dallas Morning News, 6/20/2023

June 20, 2023

Blog: Fact Check: An Expanded TRIPS Waiver is Unnecessary, 5/3/2023

May 3, 2023

C4IP Written Submission for Inv. No. 332-596, 4/26/2023

April 26, 2023

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

March 29, 2023

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

March 29, 2023

Blog: USTR: Don’t let opposition to TRIPS waiver expansion stop here, 12/6/2022

December 6, 2022

Webinar: Unpacking the Proposed TRIPS Waiver Expansion: A Conversation with Gary Locke, 12/1/2022

December 1, 2022

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

TRIPS Waiver

Op-ed: David Kappos and Andrei Iancu, “The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments,” STAT, 1/31/2024

Op-ed: Judge Paul Michel, “Waiving COVID-19 IP Protections Would Harm US Industry,” Law360, 1/4/2024

Press Release: Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver, 12/5/2023

C4IP Letter to President Biden on Covid-19 IP Waiver Proposal, 12/4/2023

Press Release: Council for Innovation Promotion Statement on ITC TRIPS Waiver Report, 10/18/2023

Op-ed: Frank Cullen, “The Biden administration is endangering intellectual property rights,” The Dallas Morning News, 6/20/2023

Blog: Fact Check: An Expanded TRIPS Waiver is Unnecessary, 5/3/2023

C4IP Written Submission for Inv. No. 332-596, 4/26/2023

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

Blog: USTR: Don’t let opposition to TRIPS waiver expansion stop here, 12/6/2022

Webinar: Unpacking the Proposed TRIPS Waiver Expansion: A Conversation with Gary Locke, 12/1/2022

Op-ed: David Kappos and Andrei Iancu, “The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments,” STAT, 1/31/2024

Op-ed: Judge Paul Michel, “Waiving COVID-19 IP Protections Would Harm US Industry,” Law360, 1/4/2024

Press Release: Council for Innovation Promotion Urges Biden Admin to Oppose IP Waiver, 12/5/2023

C4IP Letter to President Biden on Covid-19 IP Waiver Proposal, 12/4/2023

Press Release: Council for Innovation Promotion Statement on ITC TRIPS Waiver Report, 10/18/2023

Op-ed: Frank Cullen, “The Biden administration is endangering intellectual property rights,” The Dallas Morning News, 6/20/2023

Blog: Fact Check: An Expanded TRIPS Waiver is Unnecessary, 5/3/2023

C4IP Written Submission for Inv. No. 332-596, 4/26/2023

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities, 3/29/23

Blog: USTR: Don’t let opposition to TRIPS waiver expansion stop here, 12/6/2022

Webinar: Unpacking the Proposed TRIPS Waiver Expansion: A Conversation with Gary Locke, 12/1/2022

Contact

Menu